Customer Center
Login | Register

Investor Relations

  • Banner Image

Corporate Profile

<< Back

Luminex® Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. This industry depends on a broad range of tests, known as "bioassays," to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The in-house experts at Luminex have developed an innovative approach to bioassays, known as xMAP® technology. This groundbreaking technology enables companies and laboratories to perform bioassays more quickly and cost-effectively than with other systems, without sacrificing accuracy.

Luminex has been marketing the current generation of xMAP technology (formerly known as LabMAP®) worldwide since 1999. Thanks to its open-architecture platform, xMAP technology can be applied across a wide range of markets. In fact, xMAP technology-based systems are already in use by leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.

Escalating research and development spending, along with the evolution of pharmacogenomics, are fueling the growth of the drug discovery, clinical diagnostics and biomedical research markets - including both genomics and proteomics research. With this expansion of market opportunities, Luminex is strategically positioned for sustained growth and success.